Royalty Pharma (RPRX) EBT Margin (2019 - 2026)

Royalty Pharma has disclosed EBT Margin across 8 years of filings, most recently posting 74.26% for Q1 2026.

• EBT Margin for Q1 2026 came in at 74.26%, down 219.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 55.69% (down 2248.0% YoY), and the FY2025 annual result was 55.68%, down 311.0% from the prior year.
• EBT Margin came in at 74.26% for Q1 2026 at Royalty Pharma, up from 57.22% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 142.8% in Q3 2024 to a low of 107.83% in Q4 2022.
• The 5-year median for EBT Margin is 57.22% (2025), against an average of 50.53%.
• Across the five-year window, EBT Margin tumbled 11715 bps in 2022 and surged 22821 bps in 2023, its largest moves.
• Royalty Pharma's EBT Margin stood at 107.83% in 2022, then jumped by 212 bps to 120.39% in 2023, then tumbled by 53 bps to 56.32% in 2024, then climbed by 2 bps to 57.22% in 2025, then increased by 30 bps to 74.26% in 2026.
• The last three EBT Margin figures came in at 74.26% (Q1 2026), 57.22% (Q4 2025), and 72.91% (Q3 2025), per Business Quant data.